

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DISCLAIMER IN PATENT UNDER 37 CFR 1.321(a)

Name of Patentee	Foghorn Therapeutics Inc.	Docket Number (Optional)	51121-027004
Patent Number	11,414,416	Date Patent Issued	August 16, 2022
Title of Invention			
COMPOUNDS AND USES THEREOF			

I hereby disclaim the following complete claims in the above identified patent:

1-15


The extent of my interest in said patent is (if assignee of record, state liber and page, or reel and frame, where assignment is recorded): Assignee of 100% of the rights based on the assignment recorded at Reel: 059281, Frame: 0293

The fee for this disclaimer is set forth in 37 CFR 1.20(d).

- ☒ Patentee claims small entity status. See 37 CFR 1.27.
- ☒ Small entity status has already been established in this case, and is still proper.
- ☐ A check in the amount of the fee is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 03-2095

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Signed at Cambridge, State of Massachusetts,
this 21st day of August, 2023.


Signature

Adrian Gottschalk, President and CEO of Foghorn Therapeutics Inc.

Typed or printed name of patentee/ attorney or agent of record

500 Technology Square, Suite 700

Address

Cambridge, MA 02139

City, State, Zip Code or Foreign Country as applicable

Registration Number, if applicable

617-586-3100

Telephone Number